Healthcare Industry News: HSMN NewsFeed
News Release - December 22, 2011
BSD Medical Signs Exclusive Distribution Agreement with AngioCare BV for Distribution of the MicroThermX(R) Microwave Ablation Line of Products in The NetherlandsSALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an exclusive agreement with AngioCare BV (AngioCare) for the sale and distribution of the MicroThermX® Microwave Ablation (MicroThermX®) line of products in The Netherlands. AngioCare is the leading independent specialty distributor in The Netherlands, and has a successful track record in introducing innovative products to the interventional radiology market. AngioCare represents a number of major medical device companies and sells strategically adjacent products to the same clinicians targeted for the MicroThermX®.
AngioCare has purchased MicroThermX® equipment and SynchroWave antennas. AngioCare has already presented the MicroThermX® to key opinion leaders, who have expressed strong interest in clinical evaluations. BSD has provided the AngioCare sales team with extensive hands-on training to ensure success in clinical use of the system. AngioCare’s sales and distribution network will ensure that a dedicated team of medically trained sales representatives are presenting the advantages of the MicroThermX® to interventional oncologists throughout The Netherlands.
About the MicroThermX® Microwave Ablation System
The MicroThermX® is a compact, mobile, state-of-the-art proprietary system that includes a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.